Meeting
2022 ASCO Annual Meeting
Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
Authors
Indrajeet Singh
Gilead Sciences Inc., Foster City, CA
Indrajeet Singh , Abhishek G. Sathe , Pratap Singh , Paul M. Diderichsen , Floris Fauchet , John Maringwa , Philippe Pierrillas , See-Chun Phan , Sandhya Girish , Ahmed A. Othman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02574455, NCT01631552
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1076)
DOI
10.1200/JCO.2022.40.16_suppl.1076
Abstract #
1076
Poster Bd #
454
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
First Author: Joyce O'Shaughnessy
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler
Poster
2022 ASCO Annual Meeting
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Nusayba Ali Bagegni